Mediaboss Marketing

27 September 2013 Last updated at 16:28

The use of the word "Yid" in football chants by Tottenham fans has attracted comment from the FA, the police and even David Cameron, but should its use be stamped out?

Most Spurs fans are not Jewish but the club has an historical association with London's Jewish community and adoption of the Y-word by Tottenham fans is an attempt to deflect anti-Semitic abuse by rival fans, according to the club.

But what are the origins of the word and should its use be considered offensive?

...any Jewish person with any relative that experienced the Holocaust would not easily walk around anywhere shouting "Yid"

The term in itself does not have anti-Semitic connotations explains Helen Beer, a lecturer in Yiddish at University College London and a native Yiddish speaker.

"It's a very straightforwardly Yiddish word," Dr Beer says.

"So you would say 'Der Yid' which among Yiddish speakers simply means 'the Jew'.

"You also have expressions where men might greet each other informally and say 'Gut morgn Reb Yid' which simply means 'Good morning, mister'."

However, Dr Beer warns the word only retains this neutral meaning when it is used by speakers of Yiddish and, in contemporary Britain, only a low percentage of secular Jews can speak the language.

Go here to read the rest:
The Y-word: Pride or prejudice?

Press Release

Leclanch SA announces new appointment and reports supplier objection

Yverdon-les-Bains, Switzerland, September 25, 2013 - Leclanch S.A. (SIX Swiss Exchange: LECN), announced today that it has appointed Mr Thierry Perronnet to head up its Distribution Business and provided supplementary information on a supply contract.

New Appointment

Leclanch specializes in the production of large-format lithium-ion cells and energy storage solutions but also operates two existing businesses, the Portable business and the Distribution business. Mr Perronnet's appointment is in line with Leclanch's strategy to develop and grow these two existing businesses.

The Portable business, which designs and develops customer specific portable energy storage systems for military, medical and industrial applications, achieved unaudited revenues of CHF 5.0 million for the 6 months ending 30 June 2013. During the same period, unaudited revenues for the Distribution business were CHF1.6million. This business unit provides a range of consumer energy storage products to a diversified customer base.

Mr Perronnet, a French national, has a strong background in consumer goods and technological Business to Business ('B2B') markets and has held various senior positions in sales and marketing in Europe and North America. Until recently, he was a B2B Marketing Director with Eastman Kodak for the EMEA region. Prior to that he successfully developed a Business to Customer ('B2C') business in data storage and photographic products that was spun off from 3M, for whom he had previously worked in Europe and North America.

Supplier Objection

In its recent listing prospectus Leclanch noted that it had terminated a supplier contract due to quality and contamination issues with the raw material delivered by this supplier. The company had noted, at the time, that the supplier had not responded to its termination. The supplier has rejected Leclanch's position but Leclanch strongly maintains its initial position to terminate the supply agreement and will take the appropriate action as necessary.

About Leclanch

Here is the original post:
DGAP-Adhoc: Leclanché SA announces new appointment and reports supplier objection

1 0 Welcome to Word Press
Here you get all information About manage the site at wordpress.

By: Moazam Irshad

Originally posted here:
1 0 Welcome to Word Press - Video

WP Affiliate Builder Review Word press Affiliate Builder WP Affiliate Builder Scam
http://affiloramax.info/ytrr I #39;ve just finished reviewing the brand new WP Affiliate Builder software and training program and I have to say it #39;s pretty damn...

By: WP Affiliate Builder mucyy

Visit link:
WP Affiliate Builder Review Word press Affiliate Builder WP Affiliate Builder Scam - Video

DGAP-News: 4SC AG / Key word(s): Investment/Alliance Press Release: 4SC Discovery and Panoptes Pharma sign patent transfer agreement for novel compound to treat severe eye diseases

26.09.2013 / 07:30

---------------------------------------------------------------------

Press Release

4SC Discovery and Panoptes Pharma sign patent transfer agreement for novel compound to treat severe eye diseases

Planegg-Martinsried/Germany and Vienna/Austria, 26 September 2013 - 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that its wholly-owned research subsidiary 4SC Discovery GmbH has entered into a patent transfer agreement with Austrian biotechnology company Panoptes Pharma Ges.m.b.H, Vienna.

The agreement gives Panoptes Pharma full patent rights to an anti-inflammatory, small molecule substance that was discovered by 4SC Discovery and is currently in preclinical development stage. Panoptes will continue developing this substance - the immune modulator PP-001 - for therapeutic application in the field of inflammatory eye diseases with high medical need and will market the compound if development is successful. Target indications of Panoptes for the substance are uveitis and viral conjunctivitis (commonly known as 'pink eye').

In return, 4SC Discovery receives a share of 24.9% in Panoptes Pharma and is entitled to subsequent, performance-based milestone payments and royalties based on the sales revenue generated with the compound. Furthermore, 4SC Discovery has the right to use the compound in the therapeutic fields of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). In the event of the further development and/or commercialisation of the compound in RA and/or IBD by 4SC Discovery, Panoptes would be entitled to milestone payments and royalties.

Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief Scientific Officer at 4SC AG, comments: 'This partnership again demonstrates the great expertise and scientific potential of 4SC in the fields of autoimmune and inflammatory diseases. In Panoptes Pharma, we found an aspiring, young biotech company which will advance the preclinical and clinical development of our innovative compound with great dedication. We wish the highly motivated and experienced team at Panoptes great success. The equity stake in Panoptes and the agreed potential milestone payments and royalties represent an attractive opportunity for us to participate in the successful future development of our substance in the field of severe eye diseases.'

'Despite the fact that millions of patients suffer from chronic uveitis and adenoviral conjunctivitis there is no safe and well tolerable medication available to treat these eye diseases. PP-001 showed excellent efficacy and good tolerability in animal models. We are fortunate to have with 4SC Discovery a renowned and reliable partner on board and Panoptes is now in the position to furtherdevelop this promising drug candidate', explains Dr. Franz Obermayr, CEO of Panoptes Pharma.

Read the rest here:
DGAP-News: Press Release: 4SC Discovery and Panoptes Pharma sign patent transfer agreement for novel compound to treat ...